5-(3-phenyl-propyl)-1H-imidazole | 208764-98-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-phenyl-propyl)-1H-imidazole
• 英文别名: 5-(3-phenylpropyl)-1H-imidazole
• CAS: 208764-98-1
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.257
• InChiKey: UPZKEEXUCMLWIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(3-phenyl-propyl)-1H-imidazole 、 溴乙酸乙酯 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 [4-(3-phenyl-propyl)-imidazol-1-yl]-acetic acid ethyl ester 、 [5-(3-phenyl-propyl)-imidazol-1-yl]-acetic acid ethyl ester
  参考文献：
  名称：

  [EN] PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
  [FR] COMPOSÉS PHÉNYLALKYL-IMIDAZOLE-BISPHOSPHONATES

  摘要：

  本文披露了非取代或取代的苯基-烷基取代[(咪唑-1-基)-1-羟基-1-膦酸乙基]-膦酸盐化合物的制备方法或工艺，它们在制造药物配方中的使用，它们在治疗疾病中的使用，使用它们治疗疾病的方法，包括它们和/或化合物在治疗疾病中的使用的药物配方。这些化合物能够抑制过度或不适当的骨吸收。化合物的公式为(I)，其中R1和R2中的一个如规范所定义，可以是自由形式、酯形式和/或盐形式。

  公开号：

  WO2010076258A1
• 作为产物：
  描述：

  4-苯基丁醛 在 sodium cyanide 、 氨 作用下， 以 乙醇 为溶剂， 反应 25.17h， 生成 5-(3-phenyl-propyl)-1H-imidazole
  参考文献：
  名称：

  Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(ω-phenylalkyl)-1H-imidazoles

  摘要：

  The influence of lipophilic moieties attached to a 4-1H-imidazole ring on the histamine H-3 receptor activity was systematically investigated. Series of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles were prepared, with an alkyl chain varying from 2-9 methylene groups and from 1-9 methylene groups, respectively. The compounds were tested for their activity on the H-3 receptor under in vitro conditions. For the 4-(n-alkyl)-1H-imidazoles the activity is proportional to chain length, ranging from a pA(2) value of 6.3 +/- 0.2 for 4-(n-propyl)-1H-imidazoIe to a pA(2) value of 7.2 +/- 0.1 for 4-(n-decyl)-1H-imidazole. For the series 4-(omega-phenylalkyl)-4H-imidazoles an optimum in H-3 activity was found for the pentylene spacer: 4-(omega-phenylpentyl)-1H-imidazole has a pA(2) value of 7.8 +/- 0.1. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00253-9

文献信息

• PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
  申请人：Cotesta Simona

  公开号：US20110257131A1

  公开（公告）日：2011-10-20

  (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, wherein one of R 1 and R 2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.

  本发明涉及未替代或替代的苯基-烷基-替代[(咪唑-1-基)-1-羟基-1-膦酸乙基]-膦酸盐，以及其制备方法或过程，其在制药配方中的使用，其在治疗疾病中的使用，其在治疗疾病中的使用方法，包括它们和/或化合物在治疗疾病中的使用的制药配方。这些化合物能够抑制过度或不适当的骨吸收。该化合物的化学式为I，其中R1和R2中的一个如规范中所定义，可以是自由形式，酯形式和/或盐形式。
• Substituted imidazoles, their preparation and pharmaceutical compositions containing the same
  申请人：Farmos-Yhtyma Oy

  公开号：EP0034473A2

  公开（公告）日：1981-08-26

  The invention provides compounds of the formula: wherein each of R1, R2 and R3, which can be the same or different is hydrogen, chloro, bromo, fluoro, methyl, ethyl, methoxv, amino, hydroxy or nitro; R4 is hydrogen or alkyl of 1 to 7 carbon atoms; X is (R5 is hydrogen or hydroxy) and n is 1-4; and their non-toxic pharmaceutically acceptable acid addition salts. These compounds exhibitvaluable pharmacological activity and are useful in the treatment of mammals, especially as anti- hypertensive agents. Furthermore, some of the compounds have proved to possess diuretic, ß-blocking activity and/or antithrombotic activity. The compounds may be made by a variety of methods and may be incorporated in pharmaceutical compositions also comprising a compatible pharmaceutically acceptable carrier.

  本发明提供了如下式的化合物： 其中 R1、R2 和 R3（可以相同或不同）各自是氢、氯、溴、氟、甲基、乙基、甲氧基、氨基、羟基或硝基；R4 是氢或 1 至 7 个碳原子的烷基；X 是 (R5 是氢或羟基）和 n 是 1-4；以及它们的无毒药学上可接受的酸加成盐。这些化合物具有宝贵的药理活性，可用于哺乳动物的治疗，特别是作为抗高血压药物。此外，其中一些化合物已被证明具有利尿、ß-阻断活性和/或抗血栓活性。这些化合物可以通过多种方法制得，并可掺入包含相容的药学上可接受的载体的药物组合物中。
• US4568686A
  申请人：——

  公开号：US4568686A

  公开（公告）日：1986-02-04
• US4684659A
  申请人：——

  公开号：US4684659A

  公开（公告）日：1987-08-04
• Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(ω-phenylalkyl)-1H-imidazoles
  作者：Iwan J.P De Esch、Aziz Gaffar、Wiro M.P.B Menge、Henk Timmerman

  DOI：10.1016/s0968-0896(99)00253-9

  日期：1999.12

  The influence of lipophilic moieties attached to a 4-1H-imidazole ring on the histamine H-3 receptor activity was systematically investigated. Series of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles were prepared, with an alkyl chain varying from 2-9 methylene groups and from 1-9 methylene groups, respectively. The compounds were tested for their activity on the H-3 receptor under in vitro conditions. For the 4-(n-alkyl)-1H-imidazoles the activity is proportional to chain length, ranging from a pA(2) value of 6.3 +/- 0.2 for 4-(n-propyl)-1H-imidazoIe to a pA(2) value of 7.2 +/- 0.1 for 4-(n-decyl)-1H-imidazole. For the series 4-(omega-phenylalkyl)-4H-imidazoles an optimum in H-3 activity was found for the pentylene spacer: 4-(omega-phenylpentyl)-1H-imidazole has a pA(2) value of 7.8 +/- 0.1. (C) 1999 Elsevier Science Ltd. All rights reserved.